Skip to main content
Erschienen in: Endocrine Pathology 1/2020

08.02.2020

Germline Mutations in Familial Papillary Thyroid Cancer

verfasst von: Marta Sarquis, Debora C. Moraes, Luciana Bastos-Rodrigues, Pedro G. Azevedo, Adauto V. Ramos, Fabiana Versiani Reis, Paula V. Dande, Isabela Paim, Eitan Friedman, Luiz De Marco

Erschienen in: Endocrine Pathology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Thyroid cancer, predominantly of papillary histology (PTC), is a common cancer mostly diagnosed sporadically. Hereditary PTC is encountered in ~ 5% of cases and may present at an earlier age, with greater risks of metastasis and recurrence, compared with sporadic cases. The molecular basis of hereditary PTC is unknown in most cases. In this study, the genetic basis of hereditary PTC in three Brazilian families was investigated. Whole exome sequencing (WES) was carried out for probands in each family, and validated, pathogenic/likely pathogenic sequence variants (P/LPSVs) were genotyped in additional family members to establish their putative pathogenic role. Overall, seven P/LPSVs in seven novel genes were detected: p.D283N*ANXA3, p.Y157S*NTN4, p.G172W*SERPINA1, p.G188S*FKBP10, p.R937C*PLEKHG5, p.L32Q*P2RX5, and p.Q76*SAPCD1. These results indicate that these novel genes are seemingly associated with hereditary PTC, but extension and validation in other PTC families are required.
Literatur
1.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, eds (2016) SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda, MD. Available from https://seer.cancer.gov/csr/1975_2016/. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, eds (2016) SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda, MD. Available from https://​seer.​cancer.​gov/​csr/​1975_​2016/​.
2.
Zurück zum Zitat Giordano TJ. Genomic hallmarks of thyroid neoplasia (2018) Annu Rev Pathol 13:141–162.CrossRef Giordano TJ. Genomic hallmarks of thyroid neoplasia (2018) Annu Rev Pathol 13:141–162.CrossRef
3.
Zurück zum Zitat Ngan ES, Lang BH, Liu T, Shum CK, So MT, Lau DK, Leon TY, Cherny SS, Tsai SY, Lo CY, Khoo US, Tam PK, Garcia-Barceló MM (2009) A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J Natl Cancer Inst 101:162–175.CrossRef Ngan ES, Lang BH, Liu T, Shum CK, So MT, Lau DK, Leon TY, Cherny SS, Tsai SY, Lo CY, Khoo US, Tam PK, Garcia-Barceló MM (2009) A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J Natl Cancer Inst 101:162–175.CrossRef
4.
Zurück zum Zitat He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, de la Chapelle A (2009) A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Research 69:625–631.CrossRef He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, de la Chapelle A (2009) A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Research 69:625–631.CrossRef
5.
Zurück zum Zitat Pereira JS, da Silva JG, Tomaz RA, Pinto AE, Bugalho MJ, Leite V, Cavaco BM (2015) Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). Endocrine 49:204–214.CrossRef Pereira JS, da Silva JG, Tomaz RA, Pinto AE, Bugalho MJ, Leite V, Cavaco BM (2015) Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). Endocrine 49:204–214.CrossRef
6.
Zurück zum Zitat Gara SK, Jia L, Merino MJ, Agarwal SK, Zhang L, Cam M, Patel D, Kebebew E (2015) Germline HABP2 mutation causing familial nonmedullary thyroid cancer. N Engl J Med 373:448–455.CrossRef Gara SK, Jia L, Merino MJ, Agarwal SK, Zhang L, Cam M, Patel D, Kebebew E (2015) Germline HABP2 mutation causing familial nonmedullary thyroid cancer. N Engl J Med 373:448–455.CrossRef
7.
Zurück zum Zitat Tomsic J, He H, de la Chapelle A (2015) HABP2 Mutation and nonmedullary thyroid cancer. N Engl J Med 373:2086.PubMed Tomsic J, He H, de la Chapelle A (2015) HABP2 Mutation and nonmedullary thyroid cancer. N Engl J Med 373:2086.PubMed
8.
Zurück zum Zitat Tomsic J, Fultz R, Liyanarachchi S, He H, Senter L, de la Chapelle A (2016) HABP2 G534E variant in papillary thyroid carcinoma. PLoS One 11:e0146315.CrossRef Tomsic J, Fultz R, Liyanarachchi S, He H, Senter L, de la Chapelle A (2016) HABP2 G534E variant in papillary thyroid carcinoma. PLoS One 11:e0146315.CrossRef
9.
Zurück zum Zitat Tomsic J, He H, Akagi K, Liyanarachchi S, Pan Q, Bertani B, Nagy R, Symer DE, Blencowe BJ, de la Chapelle A (2015) A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. Sci Rep 5:10566.CrossRef Tomsic J, He H, Akagi K, Liyanarachchi S, Pan Q, Bertani B, Nagy R, Symer DE, Blencowe BJ, de la Chapelle A (2015) A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. Sci Rep 5:10566.CrossRef
10.
Zurück zum Zitat Cavaco BM, Batista PF, Sobrinho LG, Leite V (2008) Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J Clin Endocrinol Metab 93:4426–4430.CrossRef Cavaco BM, Batista PF, Sobrinho LG, Leite V (2008) Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J Clin Endocrinol Metab 93:4426–4430.CrossRef
11.
Zurück zum Zitat Suh I, Filetti S, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY, Clark OH (2009) Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery 146:1073–1080.CrossRef Suh I, Filetti S, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY, Clark OH (2009) Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery 146:1073–1080.CrossRef
12.
Zurück zum Zitat Sahasrabudhe R, Stultz J, Williamson J, Lott P, Estrada A, Bohorquez M, Palles C, Polanco-Echeverry G, Jaeger E, Martin L, Magdalena Echeverry M, Tomlinson I, Carvajal-Carmona LG; TCUKIN (2016) The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer. J Clin Endocrinol Metab 10:1098–1103.CrossRef Sahasrabudhe R, Stultz J, Williamson J, Lott P, Estrada A, Bohorquez M, Palles C, Polanco-Echeverry G, Jaeger E, Martin L, Magdalena Echeverry M, Tomlinson I, Carvajal-Carmona LG; TCUKIN (2016) The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer. J Clin Endocrinol Metab 10:1098–1103.CrossRef
13.
Zurück zum Zitat de Mello LEB, Araujo AN, Alves CX, de Paiva FJP, Brandão-Neto J, Cerutti JM (2017) The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian kindreds. Clin Endocrinol (Oxf) 87:113–114.CrossRef de Mello LEB, Araujo AN, Alves CX, de Paiva FJP, Brandão-Neto J, Cerutti JM (2017) The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian kindreds. Clin Endocrinol (Oxf) 87:113–114.CrossRef
14.
Zurück zum Zitat Pinheiro M, Drigo SA, Tonhosolo R, Andrade SCS, Marchi FA, Jurisica I, Kowalski LP, Achatz MI, Rogatto SR (2017) HABP2 p.G534E variant in patients with family history of thyroid and breast cancer. Oncotarget 8:40896–40905.PubMedPubMedCentral Pinheiro M, Drigo SA, Tonhosolo R, Andrade SCS, Marchi FA, Jurisica I, Kowalski LP, Achatz MI, Rogatto SR (2017) HABP2 p.G534E variant in patients with family history of thyroid and breast cancer. Oncotarget 8:40896–40905.PubMedPubMedCentral
15.
Zurück zum Zitat Choi Y, Sims GE, Murphy S, Miller JR, Chan AP (2012)Predicting the functional effect of amino acid substitutions and indels. PLoS One 7:e46688.CrossRef Choi Y, Sims GE, Murphy S, Miller JR, Chan AP (2012)Predicting the functional effect of amino acid substitutions and indels. PLoS One 7:e46688.CrossRef
16.
Zurück zum Zitat Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X (2015) Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet 24:2125–2137.CrossRef Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X (2015) Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet 24:2125–2137.CrossRef
17.
Zurück zum Zitat Wang Y, Liyanarachchi S, Miller KE, Nieminen TT, Comiskey DF Jr, Li W, Brock P, Symer DE, Akagi K, DeLap KE, He H, Koboldt DC, de la Chapelle A (2019) Identification of rare variants predisposing to thyroid cancer. Thyroid 29:946–955.CrossRef Wang Y, Liyanarachchi S, Miller KE, Nieminen TT, Comiskey DF Jr, Li W, Brock P, Symer DE, Akagi K, DeLap KE, He H, Koboldt DC, de la Chapelle A (2019) Identification of rare variants predisposing to thyroid cancer. Thyroid 29:946–955.CrossRef
18.
Zurück zum Zitat Du R, Liu B, Zhou L, Wang D, He X, Xu X, Zhang L, Niu C, Liu S (2018) Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer. Cell Death Dis 9:126.CrossRef Du R, Liu B, Zhou L, Wang D, He X, Xu X, Zhang L, Niu C, Liu S (2018) Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer. Cell Death Dis 9:126.CrossRef
19.
Zurück zum Zitat Jung EJ, Moon HG, Park ST, Cho BI, Lee SM, Jeong CY, Ju YT, Jeong SH, Lee YJ, Choi SK, Ha WS, Lee JS, Kang KR, Hong SC (2010) Decreased annexin A3 expression correlates with tumor progression in papillary thyroid cancer. Proteomics Clin Appl 4:528–537.PubMed Jung EJ, Moon HG, Park ST, Cho BI, Lee SM, Jeong CY, Ju YT, Jeong SH, Lee YJ, Choi SK, Ha WS, Lee JS, Kang KR, Hong SC (2010) Decreased annexin A3 expression correlates with tumor progression in papillary thyroid cancer. Proteomics Clin Appl 4:528–537.PubMed
20.
Zurück zum Zitat Lambert E, Coissieux MM, Laudet V, Mehlen P (2012) Netrin-4 acts as a pro-angiogenic factor during zebrafish development. J Biol Chem 287:3987–3999.CrossRef Lambert E, Coissieux MM, Laudet V, Mehlen P (2012) Netrin-4 acts as a pro-angiogenic factor during zebrafish development. J Biol Chem 287:3987–3999.CrossRef
21.
Zurück zum Zitat Xu X, Yan Q, Wang Y, Dong X (2017) NTN4 is associated with breast cancer metastasis via regulation of EMT-related biomarkers. Oncol Rep 37:449–457.CrossRef Xu X, Yan Q, Wang Y, Dong X (2017) NTN4 is associated with breast cancer metastasis via regulation of EMT-related biomarkers. Oncol Rep 37:449–457.CrossRef
22.
Zurück zum Zitat Lv B, Song C, Wu L, Zhang Q, Hou D, Chen P, Yu S, Wang Z, Chu Y, Zhang J, Yang D, Liu J (2014) Netrin-4 as a biomarker promotes cell proliferation and invasion in gastric cancer. Oncotarget 6:9794–9806. Lv B, Song C, Wu L, Zhang Q, Hou D, Chen P, Yu S, Wang Z, Chu Y, Zhang J, Yang D, Liu J (2014) Netrin-4 as a biomarker promotes cell proliferation and invasion in gastric cancer. Oncotarget 6:9794–9806.
23.
Zurück zum Zitat Jayachandran A, Prithviraj P, Lo PH, Walkiewicz M, Anaka M, Woods BL, Tan B, Behren A, Cebon J, McKeown SJ (2016) Identifying and targeting determinants of melanoma cellular invasion. Oncotarget 7:41186–41202.CrossRef Jayachandran A, Prithviraj P, Lo PH, Walkiewicz M, Anaka M, Woods BL, Tan B, Behren A, Cebon J, McKeown SJ (2016) Identifying and targeting determinants of melanoma cellular invasion. Oncotarget 7:41186–41202.CrossRef
24.
Zurück zum Zitat Eveno C, Contreres JO, Hainaud P, Nemeth J, Dupuy E, Pocard M (2013) Netrin-4 overexpression suppresses primary and metastatic colorectal tumor progression. Oncol Rep 29:73–78.CrossRef Eveno C, Contreres JO, Hainaud P, Nemeth J, Dupuy E, Pocard M (2013) Netrin-4 overexpression suppresses primary and metastatic colorectal tumor progression. Oncol Rep 29:73–78.CrossRef
25.
Zurück zum Zitat Latil A, Chêne L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O (2003) Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer 103:306–315.CrossRef Latil A, Chêne L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O (2003) Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer 103:306–315.CrossRef
26.
Zurück zum Zitat Zhang J, Zheng F, Yu G, Yin Y, Lu Q (2013) miR-196a targets netrin 4 and regulates cell proliferation and migration of cervical cancer cells. Biochem Biophys Res Commun 440:582–588.CrossRef Zhang J, Zheng F, Yu G, Yin Y, Lu Q (2013) miR-196a targets netrin 4 and regulates cell proliferation and migration of cervical cancer cells. Biochem Biophys Res Commun 440:582–588.CrossRef
27.
Zurück zum Zitat Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK, Jo HJ, Kim HS, Oh N, Song GA, Park DY (2015) Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget 6:20312–20326.PubMedPubMedCentral Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK, Jo HJ, Kim HS, Oh N, Song GA, Park DY (2015) Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget 6:20312–20326.PubMedPubMedCentral
28.
Zurück zum Zitat Farshchian M, Kivisaari A, Ala-Aho R, Riihilä P, Kallajoki M, Grénman R, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM (2011) Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 179:1110–1119.CrossRef Farshchian M, Kivisaari A, Ala-Aho R, Riihilä P, Kallajoki M, Grénman R, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM (2011) Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 179:1110–1119.CrossRef
29.
Zurück zum Zitat Vierlinger K, Mansfeld MH, Koperek O, Nöhammer C, Kaserer K, Leisch F (2011) Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics 4:30.CrossRef Vierlinger K, Mansfeld MH, Koperek O, Nöhammer C, Kaserer K, Leisch F (2011) Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics 4:30.CrossRef
30.
Zurück zum Zitat Matta J, Morales L, Dutil J, Bayona M, Alvarez C, Suarez E (2013) Differential expression of DNA repair genes in Hispanic women with breast cancer. Mol Cancer Biol 1:54.PubMedPubMedCentral Matta J, Morales L, Dutil J, Bayona M, Alvarez C, Suarez E (2013) Differential expression of DNA repair genes in Hispanic women with breast cancer. Mol Cancer Biol 1:54.PubMedPubMedCentral
31.
Zurück zum Zitat Liu Y, Lusk CM, Cho MH, Silverman EK, Qiao D, Zhang R, Scheurer ME, Kheradmand F, Wheeler DA, Tsavachidis S, Armstrong G, Zhu D, Wistuba II, Chow CB, Behrens C, Pikielny CW, Neslund-Dudas C, Pinney SM, Anderson M, Kupert E, Bailey-Wilson J, Gaba C, Mandal D, You M, de Andrade M, Yang P, Field JK, Liloglou T, Davies M, Lissowska J, Swiatkowska B, Zaridze D, Mukeriya A, Janout V, Holcatova I, Mates D, Milosavljevic S, Scelo G, Brennan P, McKay J, Liu G, Hung RJ, Christiani DC, Schwartz AG, Amos CI, Spitz MR (2018) Rare variants in known susceptibility loci and their contribution to risk of lung cancer. J Thorac Oncol 13:1483–1495.CrossRef Liu Y, Lusk CM, Cho MH, Silverman EK, Qiao D, Zhang R, Scheurer ME, Kheradmand F, Wheeler DA, Tsavachidis S, Armstrong G, Zhu D, Wistuba II, Chow CB, Behrens C, Pikielny CW, Neslund-Dudas C, Pinney SM, Anderson M, Kupert E, Bailey-Wilson J, Gaba C, Mandal D, You M, de Andrade M, Yang P, Field JK, Liloglou T, Davies M, Lissowska J, Swiatkowska B, Zaridze D, Mukeriya A, Janout V, Holcatova I, Mates D, Milosavljevic S, Scelo G, Brennan P, McKay J, Liu G, Hung RJ, Christiani DC, Schwartz AG, Amos CI, Spitz MR (2018) Rare variants in known susceptibility loci and their contribution to risk of lung cancer. J Thorac Oncol 13:1483–1495.CrossRef
32.
Zurück zum Zitat Garnaas MK, Moodie KL, Liu ML, Samant GV, Li K, Marx R, Baraban JM, Horowitz A, Ramchandran R (2008) Syx, a RhoA guanine exchange factor, is essential for angiogenesis in vivo. Circ Res 103:710–716.CrossRef Garnaas MK, Moodie KL, Liu ML, Samant GV, Li K, Marx R, Baraban JM, Horowitz A, Ramchandran R (2008) Syx, a RhoA guanine exchange factor, is essential for angiogenesis in vivo. Circ Res 103:710–716.CrossRef
33.
Zurück zum Zitat Dachsel JC, Ngok SP, Lewis-Tuffin LJ, Kourtidis A, Geyer R, Johnston L, Feathers R, Anastasiadis PZ (2013) The Rho guanine nucleotide exchange factor Syx regulates the balance of dia and ROCK activities to promote polarized-cancer-cell migration. Mol Cell Biol 33:4909–4918.CrossRef Dachsel JC, Ngok SP, Lewis-Tuffin LJ, Kourtidis A, Geyer R, Johnston L, Feathers R, Anastasiadis PZ (2013) The Rho guanine nucleotide exchange factor Syx regulates the balance of dia and ROCK activities to promote polarized-cancer-cell migration. Mol Cell Biol 33:4909–4918.CrossRef
34.
Zurück zum Zitat Romano S, D'Angelillo A, Romano MF (2015) Pleiotropic roles in cancer biology for multifaceted proteins FKBPs. Biochim Biophys Acta 1850:2061–2068.CrossRef Romano S, D'Angelillo A, Romano MF (2015) Pleiotropic roles in cancer biology for multifaceted proteins FKBPs. Biochim Biophys Acta 1850:2061–2068.CrossRef
35.
Zurück zum Zitat Ge Y, Xu A, Zhang M, Xiong H, Fang L, Zhang X, Liu C, Wu S (2016) FK506 binding protein 10 is overexpressed and promotes renal cell carcinoma. Urol Int 98:169–176.CrossRef Ge Y, Xu A, Zhang M, Xiong H, Fang L, Zhang X, Liu C, Wu S (2016) FK506 binding protein 10 is overexpressed and promotes renal cell carcinoma. Urol Int 98:169–176.CrossRef
36.
Zurück zum Zitat Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN (2013) FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol 42:912–920.CrossRef Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN (2013) FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol 42:912–920.CrossRef
37.
Zurück zum Zitat Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293–303.CrossRef Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293–303.CrossRef
38.
Zurück zum Zitat Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, McGrouther DA, Burnstock G (2013) Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Invest Dermatol 121:315–327.CrossRef Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, McGrouther DA, Burnstock G (2013) Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Invest Dermatol 121:315–327.CrossRef
39.
Zurück zum Zitat Gao P, He M, Zhang C, Geng C (2018) Integrated analysis of gene expression signatures associated with colon cancer from three datasets. Gene 654:95–102.CrossRef Gao P, He M, Zhang C, Geng C (2018) Integrated analysis of gene expression signatures associated with colon cancer from three datasets. Gene 654:95–102.CrossRef
42.
Zurück zum Zitat Peiling Yang S, Ngeow J. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocr Relat Cancer. 2016 Dec;23(12):R577-R595CrossRef Peiling Yang S, Ngeow J. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocr Relat Cancer. 2016 Dec;23(12):R577-R595CrossRef
Metadaten
Titel
Germline Mutations in Familial Papillary Thyroid Cancer
verfasst von
Marta Sarquis
Debora C. Moraes
Luciana Bastos-Rodrigues
Pedro G. Azevedo
Adauto V. Ramos
Fabiana Versiani Reis
Paula V. Dande
Isabela Paim
Eitan Friedman
Luiz De Marco
Publikationsdatum
08.02.2020
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 1/2020
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-020-09607-4

Weitere Artikel der Ausgabe 1/2020

Endocrine Pathology 1/2020 Zur Ausgabe

Neu im Fachgebiet Pathologie